Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Cypherpunk Q2 2026 results show ZEC gains and Leap Phase 3 progress

Aug 12, 2026, 7:10 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

material Q2 earnings strength driven by a one-time ZEC unrealized gain, plus substantive progress on Leap's Phase 3 pathway and regulatory alignment; multiple price-relevant catalysts could lift CYPH over 6–12 months, especially if ZEC price remains elevated and Leap advances.

AI summary

What happened, with direct paths to the underlying reporting

Cypherpunk posted Q2 2026 net income of $39.4M, aided by a $46M unrealized ZEC gain; ZEC holdings reached 323,394.38 at an average cost of $341.83, about 1.92% of circulating supply. Leap Therapeutics reached FDA alignment for a Phase 3 sirexatamab trial in DKK1-high mCRC, with strategic options including a spin-out or partner financing.

ZEC treasury rose to 323,394.38 coins at $341.83 avg. Represents ~1.92% of supply.
Leap Therapeutics Phase 3 alignment with FDA for sirexatamab in DKK1-high mCRC; strategic path being explored.
FDA Fast Track designation awarded for sirexatamab in May 2026.
Q2 net income $39.4M, $0.18 per diluted share; $46.0M unrealized ZEC gain boosted results.
ZEC price moved 243.35 to 400.09 in quarter; unrealized gains linked to crypto treasury.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.